Research ArticlesInhibiting the Gastric Burst Release of Drugs from Enteric Microparticles: The Influence of Drug Molecular Mass and Solubility
Section snippets
INTRODUCTION
The last two decades witnessed the emergence of microencapsulation technology in pharmaceutical formulations,1., 2. which provided a unique platform for delayed and site-specific oral drug delivery.3 Modified release microparticles provide several advantages over conventional enteric and delayed release formulations such as larger surface area, potentially more uniform gastric emptying, and a more consistent drug release profile. Unfortunately, the particulate nature and large surface area are
Materials
Paracetamol was supplied by Knoll AG (Ludwigshafen, Germany) and prednisolone was obtained from Sanofi-Aventis (Romainville, France). Budesonide and amprenavir were gifts from Astra Zeneca (Loughborough, UK), and GlaxoSmithKline (Harlow, UK), respectively. Ketoprofen, salicylic acid, dipyridamole, cinnarizine, bendroflumethiazide, sorbitan sesquioleate (Span 83, Arlacel 83) and liquid paraffin were purchased from Sigma-Aldrich (Poole, UK). Methacrylate polymers, Eudragit S and Eudragit L, were
Microsphere Properties
All nine drugs were successfully encapsulated into Eudragit L and Eudragit S microparticles. The particles were spherical and had a uniform size distribution of 27–60 and 36–56 mm for Eudragit L and Eudragit S, respectively (Tab. 1). Representative SEM images of amprenavir and prednisolone loaded microparticles are shown in Fig. 1. According to the SEM images, there was no evidence of porosity in any of the fabricated microparticles. In addition, X-ray powder diffraction and thermal analysis
CONCLUSIONS
Nine drugs with different chemical natures were encapsulated in Eudragit L and Eudragit S microparticles using a novel emulsion solvent evaporation method. This showed the universality of the employed method for the preparation of delayed release particulate formulations. The particles had the desirable properties of spherical morphology, smooth surface, small microsphere size (< 100 μm) and a uniform size distribution. However, all the drug-loaded microparticles did not conform to USP
REFERENCES (21)
- et al.
Spray dried Eudragit microparticles as encapsulation devices for vitamin C
Int J Pharm
(2002) - et al.
Preparation, characterization, and in vivo anti-ulcer evaluation of panto- prazole-loaded microparticles
Eur J Pharm Biopharm
(2006) - et al.
Sodium pantoprazole-loaded enteric microparticles prepared by spray drying: Effect of the scale of production and process validation
Int J Pharm
(2006) - et al.
Effect of viscosity and concentration of wall former, emulsifier and pore-inducer on the properties of amoxicillin microcapsules prepared by emulsion solvent evaporation
Farmaco
(2005) - et al.
The robustness and flexibility of an emulsion solvent evaporation method to prepare pH-responsive microparticles
Int J Pharm
(2009) - et al.
Drug distribution in enteric microparticles
Int J Pharm
(2009) - et al.
Fabrication and in vivo evaluation of highly pH-responsive acrylic microparticles for targeted gastrointestinal delivery
Eur J Pharm Sci
(2009) - et al.
Physical and chemical factors influencing the release of drugs from acrylic resin films
J Pharm Sci
(1990) - et al.
Effect of hydrogen bonding interactions on the release mechanism of felodipine from nanodispersions with polyvinylpyrrolidone
Eur J Pharm Biopharm
(2006) - et al.
Preparation of prolonged-release spherical micromatrix of ibuprofen with acrylic polymer by the emulsionsolvent diffusion method for improving bioavailability
Chem Pharm Bull (Tokyo)
(1989)
Cited by (20)
An innovative wax-based enteric coating for pharmaceutical and nutraceutical oral products
2020, International Journal of PharmaceuticsFixed dose combinations for cardiovascular treatment via coaxial electrospraying: Coated amorphous solid dispersion particles
2020, International Journal of PharmaceuticsCitation Excerpt :After 150 min, the concentration of FEN dropped again due to the increased precipitation propensity of the highly supersaturated FEN. Interestingly, in a study from Alhnan et al., that investigated the release in acidic condition of APIs with different physicochemical characteristics embedded in Eudragit S® microparticles, the burst release from these matrix particles was correlated to the molecular weight of the APIs rather than the solubility (Alhnan et al., 2010). Although in this work, coated particles instead of matrix particles are covered and the described correlation is not fully fulfilled, the molecular weight of ATE and PAR is lower than that of LOV and FEN, which possibly can favour diffusion.
High precision microfluidic microencapsulation of bacteriophages for enteric delivery
2018, Research in MicrobiologyCitation Excerpt :Larger particles (∼mm size range) may be more prone to the influence of short transit times. Smaller particles predisposed to non-specific mucoadhesion which may aid in phage retention and sustained release over a significant time period [56,57]. A recent study showed better phage retention (for animals treated with alginate encapsulated phages versus those treated with free phages) in the caecum of chickens and a significant reduction in Salmonella colonisation [39].
On demand manufacturing of patient-specific liquid capsules via co-ordinated 3D printing and liquid dispensing
2018, European Journal of Pharmaceutical SciencesColonic delivery of indometacin loaded PGA-co-PDL microparticles coated with Eudragit L100-55 from fast disintegrating tablets
2017, International Journal of PharmaceuticsA novel dense CO<inf>2</inf> supercritical fluid technology for the development of microparticulate delivery systems containing ketoprofen
2012, European Journal of Pharmaceutics and BiopharmaceuticsCitation Excerpt :The percentage of Eudragit L100 and S100 used in these formulations is not sufficient to drastically limit the drug release rate in acidic environment. Generally, the principal application of these methacrylic acid copolymers is as enteric film coating agents [24–26], but they can be also used as binder to prepare pellets, granules, and microparticulate systems and are suitable for melt-extrusion process [27–31]. In the latter case, the supplier suggests to use in the formulation 10–50% of polymer, underling that the required polymer quantity may vary according to surface texture, mechanical stability, or solubility of the active pharmaceutical ingredient [32].